NEUROSENSE THERAPEUTICS LTD. (NRSN)
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business